Fig. 1

METTL7B was overexpressed in TKIs-resistant LUAD cells. a Bioinformatics analysis of the differential expression of METTL family between PC9 and PC9-GR cells from Gene Expression Omnibus (GEO) databases GSE74253. b and c qRT-PCR and immunoblot analysis on the expression of METTL7B in PC9, PC9-GR and PC9-OR cells. d The TKI-resistant PDX and CDX tumor models. e-l Patient-derived tumors were implanted into the flank of BALB/c nude mice to form subcutaneous tumors. The mice with subcutaneously implanted tumors were treated with gefitinib or osimertinib (30 mg/kg, qd, po). The tumor volumes were presented from five mice per group. At the end of experiment, the tumors were taken out and METTL7B mRNA and protein levels were evaluated. m-p The same experiments with (e-l) but in PC9 cell-derived xenograft tumors. Quantification of relative METTL7B mRNA levels from three independent experiments were shown. *P < 0.05, **P < 0.01, ***P < 0.001